Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [¹⁷⁷Lu]Lu-OPS201 Compared to the Agonist [¹⁷⁷Lu]Lu-DOTA-TATE

• Hauptverfasser: Rosalba Mansi (Verfasst von), Pascale Plas (Verfasst von), Georges Vauquelin (Verfasst von), Melpomeni Fani (Verfasst von)
• Format: Buch
• Veröffentlicht: MDPI AG, 2021-12-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Treatment of neuroendocrine tumours with the radiolabelled somatostatin receptor subtype 2 (SST₂) peptide agonist [¹⁷⁷Lu]Lu-DOTA-TATE is effective and well-established. Recent studies suggest improved therapeutic efficacy using the SST<sub>2</su...